semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-60.0,  Bone Density Bone Loss Anorexia Nervosa Eating Disorder Atypical Anorexia Nervosa Inclusion/  Female Age 20-60 years, skeletally mature with closed epiphyses Anorexia nervosa or atypical anorexia nervosa defined by DSM-V diagnostic BMD T-score < -1.0 Normal serum 25-OH vitamin D (>30 ng/mL) and calcium levels For women of reproductive age, agree to use an effective contraceptive method. Highly effective methods of birth control Combined (estrogen and progestogen) hormonal methods (pills, vaginal ring, or skin patch) Intrauterine device (IUD) Intraduterine hormonal-releasing system (IUS) Surgery to tie both fallopian tubes (bilateral tubal ligation/occlusion)
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 4.0-18.0,  Tooth Decay Children of at least 4 years of good general health (ASAI or II) Child with at least two temporary molars of the same type, 1st or 2nd molar, contralateral (fractional mouth), meeting the following The two temporary molars are affected by a cavitary carious lesion or a hypoplastic defect of at least 2 faces the two temporary molars of the pair (54-64, 55-65, 74-84 or 75-85), should or should not be subjected to pulpotomy prior to the realization of the CPP the two molars must have an antagonistic tooth Consent of parents (legal guardians) and child Child and parents (legal guardians) speaking French Child covered by his parents' social security cover Child cooperating in the vigilant or sedated state (cooperation evaluated with a Venham score 0, 1, 2)  Child who does not cooperate in care under vigil or under conscious sedation, who must therefore be treated under general anesthesia Child allergic to local anesthetics, chromium or nickel. dental Primary molar whose physiological exfoliation will appear within 24 months or pimary molar with a root resorption of more than a third of the radicular length Severely decayed PM prohibiting the retention and the sealing of the restoration Primary molar with exposed cement or with evidence of swelling in the surrounding tissues Molar with spontaneous pain Primary molar in infraclusion Primary molar whose radiographic examination reveals a widening of the desmodontal space, the presence of radiolucent image on the root furcation and/or apices, internal or external resorption
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Burnout, Professional Criteria:Preschool classroom teacher who works in a center that is under the auspice of the School District of Philadelphia and serves exclusively low-income (≤300 % of poverty) children
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Prostate Cancer Patient at the age of 18 or above Patients with clinical diagnosis of prostate cancer  Patients diagnosed to have ductal type of prostate cancer
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Pain Edema Wound Heal Male and female patients with an age of 18 to 60 years; 2. Healthy patients (American Society of Anesthesiologists Physical Status (ASA PS) index ≤ 2); 3. Sole bilateral extractions of IMTMs during the same surgery; 4. Complete root formation of tooth No. 38 and 48 at radiological examination; 5. Absence of acute inflammation and/or infection in the IMTMs area; 6. No history of nonsteroidal anti-inflammatory drug (NSAID) use in the past 4 weeks prior to surgery; 7. Same-difficulty bilateral IMTM extractions, according to both Pederson and Juodzbalys & Daugela classifications; 8. Signed informed consent  Smoking patients; 2. IMTM surgery duration difference greater than 10 minutes for each side, seeking to avoid bias; 3. Different surgical manipulations taken at each IMTM surgery site; 4. Presence of any neoplastic lesion (benign or malignant), clinically or radiologically evaluable, at the site or close to the impacted tooth; 5. Presence of any radiolucent lesion >1 cm at impacted tooth level; 6. Absence of the adjacent tooth; 7. Systemic conditions or pharmacological treatments altering oral microbiota or immunologic response; 8. Alcohol or drug abuse; 9. Pregnant or breastfeeding women; 10. Lack of compliance by the patient or any other evidence suggesting that the patient was not likely to follow the study protocol
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 40.0-80.0,  Salt Hypertension From Excess Dietary Salt Lens Opacities Salt Sensitivity Hypertension patients Non-SSH, salt-resistant HT (SRH) patients Control patients without HT, aged 40-80 years  Cataracts Diabetes Mellitus Smoking Hypo/hypercalcemia Hyperparathyroidism Eye trauma Coronary artery disease Cardiac failure Renal failure -
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 6.0-18.0,  Dental Caries Extending to Pulp Pulp Disease, Dental Patients and parents of the patients who accept to participate and sign the informed consent Patients who have at least one vital permanent molar teeth with irreversible pulpitis symptoms Teeth which can be restorable after the treatment Teeth which has good periodontal health and in the absence of sinus tracts or swelling  Patients and parents of the patients who does not accept to participate and sign the informed consent Teeth which have dentoalveolar or extraoral swelling Teeth which have periodontal disease, mobility or alveolar bone loss Teeth which are not restorable Patients who are not cooperative with the treatment
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 25.0-60.0,  Maxillary Sinus • Presenting a distance between alveolar crest and maxillary sinus of 2 to 9 millimeters  History of periodontal surgery at the area on the last 12 months Use of drugs that affect periodontal tissues (eg: anticonvulsants, calcium channel blockers, cyclosporine, bisphosphonates, hormone-based, contraceptives, steroids) Pregnant Smokers Diabetics History of head and neck radiotherapy
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 7.0-80.0,  Facial Injuries Age 7-80 2. Male or Female Sex 3. Patients who have sustained a facial burn and are now in the chronic phase, or any patient experiencing facial tightness or limited range of motion due to other problems, including patients s/p radiation to the head and neck, trauma, scarring and scleroderma 4. Chief complaint(s) of limited mouth opening, difficulty chewing or speaking, decreased range of motion for oral structures, and/or limited facial expressions 5. Subject or caregiver (parent or guardian, in case of pediatric population) must be able to give informed consent 6. Subject or caregiver (parent or guardian, in case of pediatric population) must be able to perform exercises at home and must be able to record time spent using the devices. 7. Participants who are undergoing other treatment methods such as use of compression garments, skin grafting, radiation or other facial surgery, etc must suspend all of these treatments for the duration of the 2 month trial. 8. Internet access including access to FaceTime, Skype or Zoom and email access if electing telehealth option for enrollment  planned or unplanned surgeries for facial skin grafting around lips or nose or oral commissure release during the upcoming 8 weeks 2. completion of any massaging or other stretching exercises or programs not specified by the investigators 3. use of new creams or topical treatments for the duration of enrollment in the study. 4. acutely burn-injured patients 5. incarceration, or pregnancy
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 45.0-70.0,  Hypocalcemia; Dietary Postmenopausal woman Low contribution of elemental calcium in the daily diet  Hypersensitivity to the active substances or to any of the excipients Renal insufficiency History of kidney or urinary stones Use in the last month of diuretics (furosemide, ethacrynic acid), aluminum salts and / or thyroid hormones Use of any other drug or experimental device during the 30 days prior to the selection
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Bell Palsy years or older exhibiting unilateral facial paralysis progressing to completion in 4 days or less  No patients from vulnerable populations as listed above will be included Subjects must be able to travel to continually during the first 12 months following enrollment During the initial visit candidates must have no associated clinical signs or symptoms consistent with other causes of facial palsy. This includes but is not limited to: auricular papules, skin rashes, parotid masses, craniofacial trauma, and the presence of other cranial or distal neuropathies excluding facial numbness, change in taste, and/or hyperacusis Patients with atypical presentations will be referred for cross-sectional imaging and excluded Patients with histories consistent with possible recent tick exposure, rashes, headaches, or excessive fatigue will be serologically tested for Lyme disease and excluded if it returns positive Pneumothorax within the last two years is the only absolute medical (FF) Patients who are epileptics, or are claustrophobic, will be carefully counseled on the risks of HBOT before being allowed to enroll Patients with severe comorbidities will undergo evaluation by their primary care doctor and require physician approval prior to enrollment
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Prostate Cancer Metastatic to Bone Male, 18 years or older Histologically confirmed prostate cancer Bone metastases (≥ 6 lesions) showing pathological uptake at bone scintigraphy WHO performance status of ≤2 Life expectancy of at least 6 months Castration-resistant disease: serum testosterone level of ≤ 1.7 nmol per liter (≤50 ng per deciliter) after bilateral orchiectomy or during maintenance treatment consisting of androgen-ablation therapy with a luteinizing hormone-releasing hormone agonist. During study treatment the maintenance androgen-deprivation therapy must be continued Baseline PSA ≥5 ng/ml with evidence of progressively increasing PSA values Symptomatic disease with either regular use of analgesic medication or treatment with external-beam radiotherapy for cancer-related bone pain within the previous 12 weeks Progression on or after treatment with docetaxel, or inability to receive docetaxel Adequate renal function (serum creatinine level ≤1.5 x ULN)  Treatment with chemotherapy within the previous 4 weeks Continuation of treatment with abiraterone or enzalutamide Previous hemibody external radiotherapy Systemic radiotherapy with radioisotopes within the previous 24 weeks Malignant lymphadenopathy ≥3cm in the short-axis diameter Presence of visceral metastases Imminent of established spinal cord compression Active uncontrolled bacterial, viral or fungal infection History of another malignancy within the last five years except adequately treated basal cell carcinoma of the skin Organ allografts requiring immunosuppressive therapy
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Greater Trochanteric Pain Syndrome Over 18 years of age 2. Symptoms consistent with GTPS present for at least 6 months 3. Radiological diagnosis of GTPS using MRI, or ultrasound scan if MRI contraindicated 4. Failed conservative management in any other care setting 5. Patient is willing and able to provide written informed consent  Lacks capacity to provide consent 2. Has hip joint osteoarthritis requiring treatment on a plain radiograph 3. Presence of confounding pathologies of the hip MRI 4. Any extensive surgery or deformity of the hip on X-ray. 5. Presence of systemic disorders -coagulopathy, active infection, immune system disorders, peripheral neuropathy, malignancy, unresolved fractures. 6. Had any surgical treatment specifically targeted at GTPS e.g. bursectomy/Ilio-tibial band lengthening 7. Pregnancy 8. Anti-coagulant therapy eg warfarin, rivaroxaban, apixaban, dabigatran 9. Haemaglobin <10g/dL or platelets < 150,000/ul 10. Unable to safely stop anti-platelet/NSAID medications eg. Recent cardiac stenting 11. Has lumbar-sacral spine pathology or a recent history of acute hip trauma 12. Has a recent history of acute sciatica 13. Is not able to attend or comply with treatment or follow-up scheduling 14. Participates in any other clinical trial